Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers: A Comprehensive Study and Review of the Literature.

CONTEXT.— The diagnostic distinction of pulmonary neuroendocrine (NE) tumors from non-small cell lung carcinomas (NSCLCs) is clinically relevant for prognostication and treatment. Diagnosis is based on morphology and immunohistochemical staining. OBJECTIVE.— To determine the diagnostic value of insulinoma-associated protein 1 (INSM1), in comparison with established NE markers, in pulmonary tumors. DESIGN.— Fifty-four pulmonary NE tumors and 632 NSCLCs were stained for INSM1, CD56, chromogranin A, and synaptophysin. In a subset, gene expression data were available for analysis. Also, 419 metastases to the lungs were stained for INSM1. A literature search identified 39 additional studies with data on NE markers in lung cancers from the last 15 years. Seven of these included data on INSM1. RESULTS.— A positive INSM1 staining was seen in 39 of 54 NE tumors (72%) and 6 of 623 NSCLCs (1%). The corresponding numbers were 47 of 54 (87%) and 14 of 626 (2%) for CD56, 30 of 54 (56%) and 6 of 629 (1%) for chromogranin A, and 46 of 54 (85%) and 49 of 630 (8%) for synaptophysin, respectively. Analysis of literature data revealed that CD56 and INSM1 were the best markers for identification of high-grade NE pulmonary tumors when considering both sensitivity and specificity, while synaptophysin also showed good sensitivity. INSM1 gene expression was clearly associated with NE histology. CONCLUSIONS.— The solid data of both our and previous studies confirm the diagnostic value of INSM1 as a NE marker in pulmonary pathology. The combination of CD56 with INSM1 and/or synaptophysin should be the first-hand choice to confirm pulmonary high-grade NE tumors. INSM1 gene expression could be used to predict NE tumor histology.

[1]  Akihiko Yoshida,et al.  Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  M. Michal,et al.  Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens. , 2019, Human pathology.

[3]  K. Jirström,et al.  Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. , 2019, Human pathology.

[4]  A. Dingemans,et al.  Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? , 2019, Histopathology.

[5]  Mark Kriegsmann,et al.  Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56 , 2018, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  A. Weissferdt.  Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation: Expanding the Spectrum of Amphicrine Carcinomas , 2018, The American journal of surgical pathology.

[7]  K. Jirström,et al.  Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases , 2018, American journal of clinical pathology.

[8]  S. Mukhopadhyay,et al.  Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections , 2018, Modern Pathology.

[9]  Haiping Liu,et al.  Differential expression of neuroendocrine markers, TTF-1, p53, and Ki-67 in cervical and pulmonary small cell carcinoma , 2018, Medicine.

[10]  S. Mukhopadhyay,et al.  Insulinoma‐associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens , 2018, Cancer cytopathology.

[11]  I. Petersen,et al.  Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors , 2018, Nature Communications.

[12]  S. Ren,et al.  Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? , 2018, Lung cancer.

[13]  H. Groen,et al.  Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome , 2017, Clinical Cancer Research.

[14]  I. Nordrum,et al.  Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation , 2017, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  M. Ladanyi,et al.  Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations , 2017, Modern Pathology.

[16]  Johan Staaf,et al.  Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  P. Illei,et al.  INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.

[18]  M. Gharib,et al.  The Diagnostic Value of TTF-1, P63, HMWK, CK7, and CD56 Immunostaining in the Classification of Lung Carcinoma , 2017, Iranian journal of pathology.

[19]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[20]  A. Nicholson,et al.  The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  D. Nonaka,et al.  High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases , 2017, The American journal of surgical pathology.

[22]  G. Fontanini,et al.  Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D , 2016, The Journal of pathology.

[23]  Xufeng Chen,et al.  Correlation of neuroendocrine features with prognosis of non-small cell lung cancer , 2016, Oncotarget.

[24]  M. Tsuboi,et al.  Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung , 2016, Clinical Cancer Research.

[25]  Mats Lambe,et al.  Profiling cancer testis antigens in non-small-cell lung cancer. , 2016, JCI insight.

[26]  Hans Brunnström,et al.  The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  N. Socci,et al.  Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets , 2016, Clinical Cancer Research.

[28]  E. Speel,et al.  An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Hao-dong Xu,et al.  hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. , 2016, Human pathology.

[30]  A. Nicholson,et al.  Testing for Neuroendocrine Immunohistochemical Markers Should Not Be Performed in Poorly Differentiated NSCCs in the Absence of Neuroendocrine Morphologic Features according to the 2015 WHO Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Takaaki Ito,et al.  Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer. , 2015, The American journal of pathology.

[32]  Makoto Nishio,et al.  Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin , 2015, Medicine.

[33]  A. Marchevsky,et al.  Diagnostic difficulties with the diagnosis of small cell carcinoma of the lung. , 2015, Seminars in diagnostic pathology.

[34]  David R. Jones,et al.  Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis , 2015, The American journal of surgical pathology.

[35]  A. Warth,et al.  Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. , 2015, The Annals of thoracic surgery.

[36]  Johan Staaf,et al.  Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.

[37]  G. Rossi,et al.  Lung Cancer Histologic and Immunohistochemical Heterogeneity in the Era of Molecular Therapies: Analysis of 172 Consecutive Surgically Resected, Entirely Sampled Pulmonary Carcinomas , 2014, The American journal of surgical pathology.

[38]  T. Chou,et al.  Pulmonary neuroendocrine tumors: Study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses , 2014, Journal of surgical oncology.

[39]  H. Tsuda,et al.  Combined high‐grade neuroendocrine carcinoma of the lung: Clinicopathological and immunohistochemical study of 34 surgically resected cases , 2014, Pathology international.

[40]  F. Pontén,et al.  A systematic analysis of commonly used antibodies in cancer diagnostics , 2014, Histopathology.

[41]  K. Jirström,et al.  Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. , 2013, American journal of clinical pathology.

[42]  D. Ettinger,et al.  Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors , 2013, Acta Cytologica.

[43]  W. Nishio,et al.  Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. , 2013, The Journal of thoracic and cardiovascular surgery.

[44]  Michael Thomas,et al.  Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. , 2013, Anticancer research.

[45]  A. Warth,et al.  Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach , 2012, Virchows Archiv.

[46]  W. Travis.  Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas , 2012, Modern Pathology.

[47]  L. Pantanowitz,et al.  The cytomorphologic spectrum of small-cell carcinoma and large-cell neuroendocrine carcinoma in body cavity effusions: A study of 68 cases , 2011, CytoJournal.

[48]  W. Hanna,et al.  Expression of TdT in Merkel cell carcinoma and small cell lung carcinoma. , 2011, American journal of clinical pathology.

[49]  D. Baskić,et al.  Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[50]  P. Morbini,et al.  Large-Cell Lung Carcinoma With Basaloid Architecture and Neuroendocrine Differentiation: A New Type of Combined Large-Cell Neuroendocrine Carcinoma , 2011, International journal of surgical pathology.

[51]  M. Lozano,et al.  Large Cell Carcinoma of the Lung: An Endangered Species? , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[52]  M. Fiegl,et al.  Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases , 2009, Virchows Archiv.

[53]  S. Takashima,et al.  Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications , 2009, Journal of Cancer Research and Clinical Oncology.

[54]  M. García-Yuste,et al.  Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung , 2007, Cancer.

[55]  R. Wood‐Baker,et al.  Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation—An Entity of No Clinical or Prognostic Significance , 2007, The American journal of surgical pathology.

[56]  M. Lai,et al.  Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A , 2006, Virchows Archiv.

[57]  Takehiko Fujisawa,et al.  Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis , 2006, Modern Pathology.

[58]  J. Slodkowska,et al.  Neuroendocrine Phenotype of Non-Small Cell Lung Carcinoma: Immunohistological Evaluation and Biochemical Study , 2005, The International journal of biological markers.

[59]  A. Nicholson,et al.  CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact , 2005, Journal of Clinical Pathology.

[60]  K. Kerr,et al.  Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy , 2005, Histopathology.

[61]  H. Asamura,et al.  hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors , 2004, Modern Pathology.

[62]  J. William Ahwood,et al.  CLASSIFICATION , 1931, Foundations of Familiar Language.

[63]  Renato Martins,et al.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[64]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[65]  G. Pelosi,et al.  Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology , 2013, Virchows Archiv.

[66]  Hemlata Jangir,et al.  Fine Needle Aspiration , 2011 .

[67]  A. Sakurada,et al.  Immunocytochemical evaluation of large cell neuroendocrine carcinoma of the lung for the more accurate preoperative diagnosis: P1-163 , 2007 .